Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:VNDA
- CUSIP: 92165910
- Web: www.vandapharmaceuticals.com
Capitalization:- Market Cap: $721.75 million
- Outstanding Shares: 44,552,000
Average Prices:- 50 Day Moving Avg: $15.39
- 200 Day Moving Avg: $14.54
- 52 Week Range: $10.98 - $18.00
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -60.37
- P/E Growth: -1.49
Sales & Book Value:- Annual Revenue: $150.17 million
- Price / Sales: 4.84
- Book Value: $2.88 per share
- Price / Book: 5.66
Profitability:- EBIDTA: ($4,590,000.00)
- Net Margins: -8.85%
- Return on Equity: -10.42%
- Return on Assets: -6.44%
Debt:- Current Ratio: 2.31%
- Quick Ratio: 2.30%
Misc:- Average Volume: 480,292 shs.
- Beta: 1.51
- Short Ratio: 5.42
Frequently Asked Questions for Vanda Pharmaceuticals (NASDAQ:VNDA)
What is Vanda Pharmaceuticals' stock symbol?
Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
How were Vanda Pharmaceuticals' earnings last quarter?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Tuesday, May, 2nd. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.04. The firm had revenue of $37.42 million for the quarter, compared to analysts' expectations of $38.35 million. Vanda Pharmaceuticals had a negative return on equity of 10.42% and a negative net margin of 8.85%. View Vanda Pharmaceuticals' Earnings History.
When will Vanda Pharmaceuticals make its next earnings announcement?
Where is Vanda Pharmaceuticals' stock going? Where will Vanda Pharmaceuticals' stock price be in 2017?
8 brokerages have issued 12 month price objectives for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $24.00. On average, they expect Vanda Pharmaceuticals' share price to reach $21.75 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.
Who are some of Vanda Pharmaceuticals' key competitors?
Some companies that are related to Vanda Pharmaceuticals include Dermira (DERM), Acceleron Pharma (XLRN), Amarin Corporation PLC (AMRN), Xencor (XNCR), Clinigen Group PLC (CLIN), Insmed (INSM), Forward Pharma A/S (FWP), Acorda Therapeutics (ACOR), Synergy Pharmaceuticals (SGYP), Aduro Biotech (ADRO), Omeros Corporation (OMER), Achaogen (AKAO), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY), ZIOPHARM Oncology (ZIOP), Five Prime Therapeutics (FPRX), NeuroDerm (NDRM) and PTC Therapeutics (PTCT).
Who are Vanda Pharmaceuticals' key executives?
Vanda Pharmaceuticals' management team includes the folowing people:
- H. Thomas Watkins, Independent Chairman of the Board
- Mihael Hristos Polymeropoulos M.D., President, Chief Executive Officer, Director
- James Patrick Kelly, Chief Financial Officer, Senior Vice President, Treasurer, Secretary
- Richard L Gulino, Senior Vice President, General Counsel, Secretary
- Gian Piero Reverberi, Senior Vice President, Acting Chief Commercial Officer and European General Manager
- Kenneth M. Bate, Director
- Michael F. Cola, Independent Director
- Richard W. Dugan, Independent Director
- Vincent J. Milano, Independent Director
Who owns Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Bank of Montreal Can (0.18%), Capital One National Association (0.04%) and Gagnon Securities LLC (0.04%). Company insiders that own Vanda Pharmaceuticals stock include James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos, Paolo Baroldi and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.
Who sold Vanda Pharmaceuticals stock? Who is selling Vanda Pharmaceuticals stock?
Vanda Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Gagnon Securities LLC and Capital One National Association. Company insiders that have sold Vanda Pharmaceuticals stock in the last year include James E Flynn and Richard L Gulino. View Insider Buying and Selling for Vanda Pharmaceuticals.
Who bought Vanda Pharmaceuticals stock? Who is buying Vanda Pharmaceuticals stock?
How do I buy Vanda Pharmaceuticals stock?
Shares of Vanda Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vanda Pharmaceuticals' stock price today?
One share of Vanda Pharmaceuticals stock can currently be purchased for approximately $16.30.
MarketBeat Community Rating for Vanda Pharmaceuticals (NASDAQ VNDA)MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Vanda Pharmaceuticals (NASDAQ:VNDA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $21.75 (33.44% upside) |
Analysts' Ratings History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/27/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight -> Overweight | $23.00 | Low |  |
| 5/26/2017 | HC Wainwright | Initiated Coverage | Buy -> Buy | $18.00 | Low | |
| 5/25/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $21.00 | Medium | |
| 4/12/2017 | CIBC | Reiterated Rating | Outperform -> Outperform | $21.00 | Low | |
| 4/12/2017 | Oppenheimer Holdings, Inc. | Initiated Coverage | Outperform | $21.00 | Low | |
| 11/9/2016 | Aegis | Initiated Coverage | Buy | $24.00 | N/A | |
| 10/10/2016 | Brean Capital | Set Price Target | Buy | $24.00 | N/A | |
| 8/26/2016 | JMP Securities | Boost Price Target | Market Outperform | $18.00 -> $22.00 | N/A | |
| 3/14/2016 | Canaccord Genuity | Reiterated Rating | Buy | $18.00 | N/A | |
(Data available from 7/21/2015 forward)
Earnings History for Vanda Pharmaceuticals (NASDAQ:VNDA)Earnings History by Quarter for Vanda Pharmaceuticals (NASDAQ VNDA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/2/2017 | | ($0.28) | | | | | N/A | |
| 5/2/2017 | Q1 2017 | ($0.13) | ($0.17) | $38.35 million | $37.42 million | View | Listen | |
| 2/15/2017 | Q416 | ($0.06) | ($0.01) | $39.38 million | $38.24 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.14) | ($0.01) | $38.05 million | $38.48 million | View | Listen | |
| 7/27/2016 | Q216 | ($0.23) | ($0.11) | $36.03 million | $36.02 million | View | Listen | |
| 5/4/2016 | Q116 | ($0.24) | ($0.17) | $32.48 million | $33.30 million | View | Listen | |
| 2/10/2016 | Q415 | ($0.26) | ($0.23) | $31.34 million | $31.85 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.20) | ($0.11) | $28.58 million | $28.34 million | View | Listen | |
| 7/29/2015 | Q2 | ($0.32) | ($0.01) | $24.55 million | $27.60 million | View | Listen | |
| 5/6/2015 | Q1 | ($0.25) | ($0.24) | $20.18 million | $22.20 million | View | Listen | |
| 2/19/2015 | Q4 | $0.56 | ($0.36) | $35.57 million | $15.40 million | View | Listen | |
| 10/27/2014 | Q314 | ($0.39) | ($0.04) | $12.20 million | $14.80 million | View | Listen | |
| 8/7/2014 | Q2 | ($0.70) | ($0.64) | $10.00 million | $10.80 million | View | Listen | |
| 5/8/2014 | Q1 | ($0.29) | ($0.79) | $8.50 million | $9.10 million | View | Listen | |
| 2/13/2014 | Q413 | ($0.20) | ($0.23) | $8.50 million | $8.80 million | View | Listen | |
| 11/7/2013 | Q313 | ($0.30) | ($0.43) | $8.45 million | $8.70 million | View | Listen | |
| 7/31/2013 | Q2 2013 | ($0.22) | ($0.26) | $8.43 million | $8.30 million | View | Listen | |
| 5/9/2013 | Q1 2013 | ($0.25) | ($0.15) | $8.42 million | $8.10 million | View | Listen | |
| 2/12/2013 | Q4 2012 | ($0.22) | ($0.23) | $8.60 million | $7.90 million | View | Listen | |
| 11/7/2012 | Q312 | ($0.22) | ($0.19) | $8.40 million | $8.28 million | View | N/A | |
| 8/2/2012 | | ($0.27) | ($0.28) | | | View | N/A | |
| 5/8/2012 | | ($0.16) | ($0.28) | | | View | N/A | |
| 2/14/2012 | | ($0.19) | ($0.20) | | | View | N/A | |
| 11/4/2011 | | ($0.12) | ($0.11) | | | View | N/A | |
| 8/4/2011 | | ($0.07) | ($0.05) | | | View | N/A | |
| 2/10/2011 | | ($0.02) | $0.08 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)2017 EPS Consensus Estimate: ($0.66)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.18) | ($0.15) | ($0.17) |
| Q2 2017 | 2 | ($0.27) | ($0.20) | ($0.24) |
| Q3 2017 | 2 | ($0.19) | ($0.14) | ($0.17) |
| Q4 2017 | 2 | ($0.14) | ($0.05) | ($0.10) |
(Data provided by Zacks Investment Research)
Dividend History for Vanda Pharmaceuticals (NASDAQ:VNDA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vanda Pharmaceuticals (NASDAQ:VNDA)Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 92.51%
Insider Trades by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 1/3/2017 | Richard L Gulino | SVP | Sell | 10,900 | $15.51 | $169,059.00 | |
| 9/23/2016 | James E Flynn | Insider | Sell | 1,120,461 | $16.56 | $18,554,834.16 | |
| 9/19/2016 | James E Flynn | Insider | Sell | 547,886 | $15.66 | $8,579,894.76 | |
| 1/4/2016 | James Patrick Kelly | CFO | Sell | 9,564 | $8.96 | $85,693.44 | |
| 1/4/2016 | Mihael Hristos Polymeropoulos | CEO | Sell | 21,353 | $8.96 | $191,322.88 | |
| 1/4/2016 | Paolo Baroldi | SVP | Sell | 12,380 | $8.96 | $110,924.80 | |
| 12/11/2015 | James E Flynn | Insider | Buy | 1,201,364 | $8.38 | $10,067,430.32 | |
| 9/10/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 131,739 | $12.68 | $1,670,450.52 | |
| 5/22/2015 | Mihael Hristos Polymeropoulos | CEO | Sell | 186,395 | $10.36 | $1,931,052.20 | |
| 3/9/2015 | Richard W Dugan | Director | Sell | 4,804 | $10.69 | $51,354.76 | |
| 12/23/2014 | James E Flynn | Insider | Buy | 162,014 | $14.40 | $2,333,001.60 | |
| 3/14/2014 | Thomas Watkins | Director | Sell | 35,000 | $17.66 | $618,100.00 | |
| 11/21/2013 | Robert Repella | SVP | Sell | 107,500 | $12.03 | $1,293,225.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Vanda Pharmaceuticals (NASDAQ:VNDA)
Latest Headlines for Vanda Pharmaceuticals (NASDAQ:VNDA)
| Source: |
|
| Date | Headline |
|---|
 | Vanda Pharmaceuticals (VNDA) Announces Negative Opinion from EMA on Fanaptum for Treatment of Schizophrenia - StreetInsider.com
www.streetinsider.com - July 21 at 8:28 AM |
 | Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017 - PR Newswire (press release)
www.prnewswire.com - July 19 at 4:09 PM |
 | Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - July 18 at 12:14 PM |
 | Vanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
finance.yahoo.com - July 17 at 10:47 AM |
| Q2 2017 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - July 17 at 7:06 AM |
| The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals
finance.yahoo.com - July 14 at 4:59 PM |
| $40.37 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - July 5 at 11:47 AM |
| Zacks: Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) to Announce -$0.23 EPS
www.americanbankingnews.com - July 3 at 10:14 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at Piper Jaffray Companies
www.americanbankingnews.com - June 27 at 9:14 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - June 26 at 10:15 AM |
 | Vanda Pharmaceuticals (VNDA) Presents At JMP Securities Life Sciences Conference 2017 - Slideshow
seekingalpha.com - June 22 at 7:37 PM |
| Vanda: Several Catalysts Coming Up - Seeking Alpha
seekingalpha.com - June 22 at 2:35 PM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : June 21, 2017
finance.yahoo.com - June 22 at 2:35 PM |
| Vanda Pharmaceuticals (VNDA) Worth a Look: Stock Jumps 8%
finance.yahoo.com - June 22 at 2:35 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 14 at 2:18 PM |
| Vanda Pharmaceuticals (VNDA) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow
seekingalpha.com - June 9 at 2:03 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - June 7 at 8:42 AM |
| Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences - PR Newswire (press release)
www.prnewswire.com - June 7 at 8:17 AM |
| -$0.23 EPS Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - June 7 at 8:04 AM |
| Vanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences
finance.yahoo.com - June 6 at 1:50 AM |
| Research Reports Initiation on Biotech Stocks -- Corcept ... - PR Newswire (press release)
www.prnewswire.com - May 30 at 3:26 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 30 at 11:04 AM |
| Vanda Pharmaceuticals' (VNDA) "Buy" Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - May 27 at 10:56 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Coverage Initiated at HC Wainwright
www.americanbankingnews.com - May 26 at 12:58 PM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 22, 2017
finance.yahoo.com - May 22 at 7:36 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Upgraded by TheStreet to C-
www.americanbankingnews.com - May 17 at 2:50 PM |
| $40.3 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - May 13 at 9:00 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Earnings of -$0.20 Per Share
www.americanbankingnews.com - May 11 at 10:44 AM |
| Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : May 9, 2017
finance.yahoo.com - May 9 at 9:44 AM |
| Analysts Set Vanda Pharmaceuticals Inc. (VNDA) Price Target at $21.71
www.americanbankingnews.com - May 8 at 11:33 PM |
 | Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer - Washington Business Journal
www.bizjournals.com - May 6 at 3:30 PM |
| ETFs with exposure to Vanda Pharmaceuticals, Inc. : May 5, 2017
finance.yahoo.com - May 6 at 1:17 AM |
| Vanda Pharmaceuticals Inc. (VNDA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 5 at 11:52 AM |
| Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q2 2017 Earnings (VNDA)
www.americanbankingnews.com - May 5 at 7:37 AM |
| Research Analysts Set Expectations for Vanda Pharmaceuticals Inc.'s Q2 2017 Earnings (VNDA)
www.americanbankingnews.com - May 5 at 7:37 AM |
| Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017
finance.yahoo.com - May 5 at 3:23 AM |
| Vanda Pharmaceuticals expands into cystic fibrosis, blood cancer
finance.yahoo.com - May 5 at 3:23 AM |
| FY2020 EPS Estimates for Vanda Pharmaceuticals Inc. (VNDA) Lowered by Analyst
www.americanbankingnews.com - May 4 at 8:04 PM |
| FY2020 Earnings Forecast for Vanda Pharmaceuticals Inc. (VNDA) Issued By Jefferies Group
www.americanbankingnews.com - May 4 at 8:04 PM |
| Somewhat Positive Press Coverage Somewhat Likely to Affect Vanda Pharmaceuticals (VNDA) Stock Price
www.americanbankingnews.com - May 4 at 4:46 PM |
| Vanda Pharmaceuticals Inc. (VNDA) Releases Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 3 at 4:58 PM |
| Vanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:53 AM |
| Edited Transcript of VNDA earnings conference call or presentation 2-May-17 8:30pm GMT
finance.yahoo.com - May 3 at 9:53 AM |
| Investor Network: Vanda Pharmaceuticals Inc. to Host Earnings Call
finance.yahoo.com - May 2 at 6:37 PM |
| Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 2 at 6:37 PM |
 | Vanda reports 1Q loss
marketbeat.com - May 2 at 6:13 PM |
| Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference - PR Newswire (press release)
www.prnewswire.com - May 2 at 8:26 AM |
| Vanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - May 1 at 7:38 PM |
| Vanda Pharmaceuticals (VNDA) Earning Somewhat Positive News Coverage, Analysis Shows
www.americanbankingnews.com - May 1 at 7:10 PM |
| Vanda Pharmaceuticals Inc. (VNDA) to Release Earnings on Tuesday
www.americanbankingnews.com - April 30 at 7:58 AM |
Vanda Pharmaceuticals (VNDA) Chart for Friday, July, 21, 2017
